Climb Bio Inc
CLYM1.700USD
+0.250+17.24%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
114.88MCap. mercado
PérdidaP/E TTM
Más Datos de Climb Bio Inc Compañía
Climb Bio, Inc., formerly Eliem Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.
Información de la empresa
Símbolo de cotizaciónCLYM
Nombre de la empresaClimb Bio Inc
Fecha de salida a bolsaAug 10, 2021
Director ejecutivoDr. Aoife M. Brennan
Número de empleados17
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 10
Dirección20 William Street
CiudadWELLESLEY HILLS
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02481
Teléfono18668572596
Sitio Webhttps://climbbio.com/
Símbolo de cotizaciónCLYM
Fecha de salida a bolsaAug 10, 2021
Director ejecutivoDr. Aoife M. Brennan
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Bo Cumbo
Mr. Bo Cumbo
Independent Director
Independent Director
--
--
Ms. Kim Cobleigh Drapkin, CPA
Ms. Kim Cobleigh Drapkin, CPA
Independent Director
Independent Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Bo Cumbo
Mr. Bo Cumbo
Independent Director
Independent Director
--
--
Ms. Kim Cobleigh Drapkin, CPA
Ms. Kim Cobleigh Drapkin, CPA
Independent Director
Independent Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RA Capital Management, LP
46.49%
Pontifax Venture Capital
7.70%
Access Industries, Inc.
7.41%
BlackRock Institutional Trust Company, N.A.
3.10%
Cantor Fitzgerald, L.P
2.96%
Other
32.32%
Accionistas
Accionistas
Proporción
RA Capital Management, LP
46.49%
Pontifax Venture Capital
7.70%
Access Industries, Inc.
7.41%
BlackRock Institutional Trust Company, N.A.
3.10%
Cantor Fitzgerald, L.P
2.96%
Other
32.32%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
54.93%
Investment Advisor
12.36%
Hedge Fund
11.49%
Corporation
7.41%
Research Firm
3.67%
Investment Advisor/Hedge Fund
2.47%
Individual Investor
0.67%
Bank and Trust
0.05%
Pension Fund
0.03%
Other
6.93%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
168
62.90M
93.07%
-4.49M
2025Q1
169
68.90M
101.99%
-1.34M
2024Q4
155
67.64M
100.63%
-51.77K
2024Q3
127
63.79M
95.46%
+1.90M
2024Q2
91
59.36M
99.92%
+31.16M
2024Q1
87
26.17M
94.38%
-3.33M
2023Q4
91
26.16M
95.54%
-3.35M
2023Q3
92
25.94M
95.83%
-3.54M
2023Q2
93
25.92M
96.06%
-3.17M
2023Q1
92
25.90M
96.01%
-3.10M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
31.42M
46.49%
--
--
Mar 31, 2025
Pontifax Venture Capital
5.21M
7.7%
+5.21M
--
Mar 31, 2025
Access Industries, Inc.
5.01M
7.41%
--
--
Aug 14, 2024
BlackRock Institutional Trust Company, N.A.
2.10M
3.1%
-10.56K
-0.50%
Mar 31, 2025
Cantor Fitzgerald, L.P
2.00M
2.96%
+1.35M
+207.37%
Mar 31, 2025
Citi Investment Research (US)
1.85M
2.74%
+1.83M
+8039.18%
Mar 31, 2025
The Vanguard Group, Inc.
1.50M
2.22%
-3.70K
-0.25%
Mar 31, 2025
Affinity Asset Advisors LLC
1.50M
2.22%
+1.00M
+200.00%
Mar 31, 2025
Kynam Capital Management LP
1.05M
1.55%
+500.00K
+91.41%
Mar 31, 2025
Deep Track Capital LP
1.04M
1.54%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Russell 2000 Value ETF
0%
Ver más
ProShares Ultra Nasdaq Biotechnology
Proporción0.01%
iShares Biotechnology ETF
Proporción0.01%
Invesco Nasdaq Biotechnology ETF
Proporción0.01%
iShares Micro-Cap ETF
Proporción0.01%
Avantis US Small Cap Equity ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
iShares Neuroscience and Healthcare ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
